Acute Gout Management with NSAIDs

Introduction to Acute Gout Treatment

The American College of Rheumatology recommends full-dose NSAIDs, including naproxen, indomethacin, and sulindac, as first-line treatments for acute gout attacks, which should be initiated within 24 hours of symptom onset for optimal effectiveness 1, 2, 3

Naproxen, indomethacin, and sulindac are specifically FDA-approved for the treatment of acute gout 3
NSAIDs should be administered at full FDA-approved anti-inflammatory/analgesic doses for acute gout treatment 1, 3

Indomethacin: Initial dose of 50 mg three times daily for 2-3 days, followed by 25 mg three times daily for an additional 3-5 days until symptoms resolve 4
Treatment should be initiated as soon as possible, ideally within 24 hours of symptom onset 2, 3

Corticosteroids are recommended as first-line therapy in patients with contraindications to NSAIDs due to their safety profile and low cost 5, 6
Low-dose colchicine (1.2 mg followed by 0.6 mg one hour later) is effective if started within 36 hours of symptom onset 1, 3, 6

For severe pain in polyarticular attacks, combination therapy may be appropriate 2
Options include combining NSAIDs with corticosteroids or colchicine, though caution is needed due to potential increased adverse effects 2, 6

NSAIDs are contraindicated in patients with severe renal impairment, history of GI bleeding or ulceration, and heart failure 4

Delaying treatment beyond 24 hours of symptom onset reduces effectiveness 2, 6
Interrupting ongoing urate-lowering therapy during an acute attack (this should be continued) 1, 3

After resolution of acute gout, prophylactic therapy should be considered when initiating urate-lowering therapy 1, 6
Prophylactic therapy should be continued for at least 8 weeks when starting urate-lowering therapy 5, 6

The American College of Physicians recommends NSAIDs, corticosteroids, and low-dose colchicine as equally effective first-line options for acute gout, with NSAIDs or corticosteroids preferred over colchicine due to superior tolerability and cost-effectiveness 7, 8
High-quality evidence demonstrates that NSAIDs effectively reduce pain in acute gout, with moderate-quality evidence showing no clinically important differences between different NSAIDs 7, 8
High-quality indirect evidence shows that systemic corticosteroids reduce pain equivalently to NSAIDs, with six RCTs demonstrating no difference in time to symptom resolution or pain reduction between NSAIDs and corticosteroids 7, 8
High-quality evidence shows that colchicine reduces pain in acute gout, with a low-dose regimen being as effective as high-dose colchicine but with significantly fewer gastrointestinal adverse effects 7, 8

NSAIDs are associated with more frequent gastrointestinal adverse events than corticosteroids in comparative trials 7, 8
Colchicine causes gastrointestinal adverse effects, including nausea, vomiting, cramps, and pain, in a substantial proportion of patients 7, 8